InsidersTradesSigma
Follow the Guardant Health, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Guardant Health, Inc. has recorded 596 insider filings. Market capitalisation: €2.4bn. The latest transaction was filed on 27 August 2026 (J). Among the most active insiders: Talasaz AmirAli. All data is openly available.
In the last 90 days, Guardant Health, Inc. reported a total of 95 insider trading declarations, with a cumulative selling amount of approximately 110.95 million euros and no reported buying activity. The top insiders involved in selling include Talasaz AmirAli, Co-Chief Executive Officer, with total sales of about 45.36 million euros across 15 declarations, Chris Freeman, Chief Commercial Officer, with approximately 22.74 million euros from 9 declarations, and Helmy Eltoukhy, Co-Chief Executive Officer, with around 21.75 million euros from 13 declarations. Significant recent sales include Talasaz AmirAli's sale of approximately 34.51 million euros on June 26, 2026, and Helmy Eltoukhy's sale of about 10.88 million euros on June 5, 2026. Other notable transactions include Chris Freeman's sale of approximately 9.33 million euros on August 10, 2026, and Terilyn J. Monroe's sale of about 6.62 million euros on August 12, 2026.
Auto-generated summary, refreshed daily.Updated 1d ago
596
Insider Decl.
n/a
Thresholds
€9m
7 ops.
Buy Volume
€64m
83 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Guardant Health, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
57Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,760 of 28,958 companies
29.2
score / 100
Value24
Quality34
FCF yld-3.6%
Earn yld-4.6%
EV/EBITDA·
ROE-40%
Gross mgn64%
Net mgn-11%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 August 2026
Declarations596 total
25,000 shares0Common StockSEC:0001752968-26-000016:0
25,000 shares0Common StockSEC:0001752968-26-000016:1
30,000 shares0Common StockSEC:0001752968-26-000016:2
264 shares0Common StockSEC:0001258394-26-000016:0
7,589 shares@ US$170.28620.056% mcap2.1% of flowCommon StockSEC:0001753159-26-000020:2
9,023 shares@ US$168.19580.065% mcap2.5% of flowCommon StockSEC:0001753159-26-000020:0
20,888 shares@ US$169.16180.15% mcap5.8% of flowCommon StockSEC:0001753159-26-000020:1
37,500 shares@ US$169.15690.27% mcap11.6% of flowCommon StockSEC144:0001972481-26-000267
232 shares0Common StockSEC:0001865525-26-000026:0
250 shares0Common StockSEC:0001968281-26-000023:0
116 shares@ US$156.450.0008% mcap2.5% of flowCommon StockSEC:0001968281-26-000023:1
116 shares@ US$156.44830.0008% mcap2.6% of flowCommonSEC144:0001921094-26-000884
32,288 shares@ US$20.140.028% mcap3.5% of flowCommon StockSEC:0001652956-26-000018:0
14,012 shares@ US$28.610.017% mcap2.1% of flowCommon StockSEC:0001652956-26-000018:1
3,704 shares@ US$163.41410.026% mcap3.2% of flowCommon StockSEC:0001652956-26-000018:2
9,934 shares@ US$164.27120.070% mcap8.7% of flowCommon StockSEC:0001652956-26-000018:3
13,248 shares@ US$166.10690.095% mcap11.8% of flowCommon StockSEC:0001652956-26-000018:5
400 shares@ US$167.91880.0029% mcap0.4% of flowCommon StockSEC:0001652956-26-000018:6
19,014 shares@ US$165.15780.14% mcap16.8% of flowCommon StockSEC:0001652956-26-000018:4
46,300 shares@ US$165.12350.33% mcap76.7% of flowCommonSEC144:0001921094-26-000839
35,000 shares0Common StockSEC:0001752968-26-000014:0
35,000 shares0Common StockSEC:0001752968-26-000014:1
75,000 shares0Common StockSEC:0001753159-26-000018:0
75,000 shares0Common StockSEC:0001753159-26-000018:1
800 shares0Common StockSEC:0001737840-26-000020:0
25 of 596 declarations
About Guardant Health, Inc.
Guardant Health, Inc. is a U.S.-based precision oncology and liquid biopsy company listed on the NASDAQ under ticker GH. Headquartered in Palo Alto, California, in the United States, the company was founded in 2012 and has built a differentiated platform focused on using blood-based testing, tissue testing, clinical datasets, and AI analytics to help clinicians detect, characterize, and monitor cancer more effectively. It has become one of the best-known names in molecular diagnostics for oncology. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Surpasses-500-Peer-Reviewed-Publications-Milestone/default.aspx?utm_source=openai)) Guardant’s business model is organized around three main pillars. The Oncology segment includes liquid and tissue-based genomic testing for patients with advanced and early-stage cancers. The Screening segment is centered on cancer screening, most notably Shield, the company’s blood test for colorectal cancer screening. The Biopharma & Data business monetizes real-world clinical-genomic data and related services for pharmaceutical partners, supporting drug development and the creation of companion diagnostics. Key products in the portfolio include Guardant360 Liquid, Guardant360 CDx, Guardant360 Tissue, Guardant Reveal, and Shield. ([about.guardanthealth.com](https://about.guardanthealth.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/?utm_source=openai)) From a competitive standpoint, Guardant Health is among the global leaders in liquid biopsy. Its edge comes from the scale and depth of its data assets, its scientific publication record, clinical adoption across major cancer centers, and its ability to move assays into FDA-cleared companion diagnostic roles and reimbursement pathways. The company stated in 2024 that it had surpassed 500 peer-reviewed publications featuring its technology, underscoring its scientific credibility in a highly competitive field. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Surpasses-500-Peer-Reviewed-Publications-Milestone/default.aspx?utm_source=openai)) Recent milestones have been material. In January 2026, Guardant received additional FDA approvals for Guardant360 CDx, including in BRAF V600E-mutant metastatic colorectal cancer, and on May 4, 2026, in ESR1-mutated ER+/HER2- advanced breast cancer. In March 2026, Shield became more widely accessible through Quest Diagnostics’ national ordering and collection network. Guardant also announced a multi-year strategic collaboration with Merck in January 2026, reinforcing the company’s companion-diagnostics and smart-platform strategy. In its 2026 outlook, the company guided to full-year revenue of $1.25 billion to $1.28 billion. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-BRAFTOVI-encorafenib-Combination-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer/default.aspx?utm_source=openai)) For investors in France, Belgium, and Switzerland, Guardant Health remains a growth-oriented healthcare name with strong strategic positioning, but it is still dependent on commercial execution, reimbursement expansion, and broader clinical adoption of blood-based cancer diagnostics on the NASDAQ market in the United States.
